Assembly Biosciences expands ABI-6250 into two new liver diseases, Phase 2 trials to start Q4 2026
Filed May 22, 2026 · Period ending May 22, 2026 · ~1 min read
4 material changes detected in this filing.
Create a free account to read the full summary — it takes 30 seconds.
Partner
Trade ASMB commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
View original filing on SEC.gov
Generated by AI · May 27, 2026 4:05 AM